Abnova Taiwan Corp. (4133) Stock Price & Analysis
4133 Stock Chart & Stats
- Day’s Range
- TWD 19.00 - TWD 19.80
- 52-Week Range
- TWD 19.00 - TWD 29.15
- Previous Close
- TWD 19.85
- Volume
- N/A
- Average Volume (3M)
- 202.88K
- Market Cap
- TWD 1.18B
- Enterprise Value
- TWD 849.23M
- Total Cash (Recent Filing)
- TWD 406.17M
- Total Debt (Recent Filing)
- TWD 17.06M
- Price to Earnings (P/E)
- 26.4
- Beta
- 0.47
- Next Earnings
- Nov 11, 2026 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jun 16, 2026
- Dividend Yield
- 0.57%
4133 FAQ
What was Abnova Taiwan Corp.’s price range in the past 12 months?
What is Abnova Taiwan Corp.’s market cap?
When is Abnova Taiwan Corp.’s upcoming earnings report date?
How were Abnova Taiwan Corp.’s earnings last quarter?
Is Abnova Taiwan Corp. overvalued?
Does Abnova Taiwan Corp. pay dividends?
What is Abnova Taiwan Corp.’s EPS estimate?
How many shares outstanding does Abnova Taiwan Corp. have?
What happened to Abnova Taiwan Corp.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Abnova Taiwan Corp.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Abnova Taiwan Corp.
Abnova (Taiwan) Corporation specializes in the development and distribution of a comprehensive range of recombinant proteins and antibodies. The company's extensive product portfolio caters to diverse research and diagnostic applications, featuring specialized reagents for SARS-CoV/CoV-2, nucleic acids (both DNA and RNA), and various proteins and peptides. Their offerings further include items like DNAxPab, laboratory beads, dyes, cellular lysates, microscopic slides, antibody pairs and associated kits, as well as antibody and tissue arrays. Additionally, they provide in situ hybridization products, advanced laboratory systems and automation, GMP-grade and analyte-specific reagents, and solutions for in vitro diagnostics. Beyond these product lines, Abnova supplies a broad spectrum of antibody types, such as MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and those specifically targeting circulating rare cells. The company also delivers integrated solutions and services, encompassing gene synthesis and cytogenetic analysis, peptide services, protein expression and conjugations, custom antibody generation, and assay development. Abnova (Taiwan) Corporation operates from its headquarters in Taipei, Taiwan.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Peiru Ji
- Employees
- 110
- Website
- www.abnova.com.tw
- Address
- No. 108, Jhouzih Street, Taipei, TPE, 114, TW
Abnova Taiwan Corp. (4133) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |

